Injectafer, made by Daiichi Sankyo, is a ferric carboxymaltose injection treatment for iron deficiency in adult patients with heart failure to improve exercise capacity, according to a June 5 company news release. It has already been approved in 86 countries since 2007 and is the most extensively studied IV iron treatment.
FDA approves 1st iron IV treatment for heart failure patients
The FDA approved the first intravenous iron replacement therapy for adults with heart failure.
Leave a Reply